secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0001549595-25-000086
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix bexobrutideg shows 80.9% ORR in CLL, 84.2% in WM; pivotal trials on track for 2025
--------------------------------------------------------------------------------

- ORR 80.9% in CLL/SLL (n=47 evaluable); median time to first response 1.9 months; one complete response after >2 years.
- ORR 84.2% in WM (n=19 evaluable); included 10.5% VGPR, 57.9% PR; IgM reductions >90% in three patients.
- Well tolerated across 50-600 mg doses; common AEs low-grade purpura/contusion (45.8%), neutropenia (29.2%); no new atrial fibrillation.
- Patients heavily pretreated: median 4 prior lines, 97.9% prior BTKi, 83.3% prior BCL2i; responses seen regardless of baseline mutations or CNS involvement.
- Nurix on track to initiate pivotal trials of bexobrutideg in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000086/0001549595-25-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000086/nrix-20250612.htm
  HTML page:      https://secwatch.observer/filing/0001549595-25-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer